Terns Pharmaceuticals (TERN) Amortization of Deferred Charges (2020 - 2023)
Terns Pharmaceuticals' Amortization of Deferred Charges history spans 4 years, with the latest figure at -$1.7 million for Q4 2023.
- For Q4 2023, Amortization of Deferred Charges fell 197.35% year-over-year to -$1.7 million; the TTM value through Dec 2023 reached -$5.2 million, down 6535.8%, while the annual FY2025 figure was -$58000.0, 97.22% up from the prior year.
- Amortization of Deferred Charges reached -$1.7 million in Q4 2023 per TERN's latest filing, up from -$1.7 million in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $613000.0 in Q1 2022 to a low of -$1.7 million in Q3 2023.
- Average Amortization of Deferred Charges over 4 years is -$324307.7, with a median of -$3000.0 recorded in 2021.
- Peak YoY movement for Amortization of Deferred Charges: skyrocketed 20533.33% in 2022, then tumbled 6626.92% in 2023.
- A 4-year view of Amortization of Deferred Charges shows it stood at $37000.0 in 2020, then soared by 424.32% to $194000.0 in 2021, then tumbled by 391.75% to -$566000.0 in 2022, then crashed by 197.35% to -$1.7 million in 2023.
- Per Business Quant, the three most recent readings for TERN's Amortization of Deferred Charges are -$1.7 million (Q4 2023), -$1.7 million (Q3 2023), and -$975000.0 (Q2 2023).